Disease-specific signatures of circulating extracellular vesicles detected by the surface plasmon resonance imaging: a pilot study

• Published in: Extracellular Vesicles and Circulating Nucleic Acids 2025-02, Vol.6 (1), p.36-53
• Main Authors: Shibuta, Tatsuki, Takada, Yukichi, Nishinosono, Shiori, Yasuda, Seiko, Ono, Yasuhiro, Hirooka, Yoshitaka, Irikura, Daisuke, Saito, Kensuke, Umemura, Tsukuru
• Format: Article
• Language: English
• ISSN: 2767-6641; 2767-6641
• DOI: 10.20517/evcna.2024.82

Aim: Cells in the human body release extracellular vesicles (EVs) into fluids, such as plasma, urine, and cerebrospinal fluid. EVs express tetraspanin family proteins (e.g., CD63, CD9, and CD81) and cell-specific antigens on their surface as common and specific markers, respectively. In this study, we hypothesized that the profile of blood cell-derived circulating EVs could reveal both common and specific pathophysiology in atherogenic diseases. Methods: Using surface plasmon resonance imaging (SPRi), we analyzed EVs surface molecules and identified circulating EVs in healthy controls (n = 18), patients with type 2 diabetes mellitus (T2DM; n = 71), and those with hypertension (HT; n = 47). Results: Patients with T2DM and HT exhibited distinct EV profiles: (i) CD9, CD110, CD20, activin receptor type-2A (AcvRIIA), Duffy antigen receptor for chemokine, and CD44 positive EVs were upregulated in T2DM; (ii) CD9, Maackia amurensis agglutinin lectin binding molecules (MBM), CD20, AcvRIIA, and CD44 positive EVs were upregulated in HT. By analyzing an appropriate set of three antigens or using dimensional reduction clustering, we were able to clearly differentiate between T2DM, HT, and control groups. In some patients, disease severity correlated with CD44 and CD20 in T2DM and MBM and AcvRIIA in HT. Conclusion: Our findings demonstrate that profiling of circulating EVs via the SPRi method offers a novel approach for diagnosing and monitoring human diseases.